Anyanwagu, Uchenna <br/><br/>
Cardiovascular events and all-cause mortality with insulin versus glucagon-like peptide-1 analogue in type 2 diabetes.  [electronic resource] 

 -  Heart (British Cardiac Society)  10 2016 
 - 1581-7 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Observational Study 
<br/><br/><label>ISSN: </label>1468-201X 
<br/><br/><label>Standard No.: </label>10.1136/heartjnl-2015-309164  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Biomarkers--blood<br/>Blood Glucose--drug effects<br/>Cardiovascular Diseases--diagnosis<br/>Cause of Death<br/>Databases, Factual<br/>Diabetes Mellitus, Type 2--complications<br/>Drug Therapy, Combination<br/>Female<br/>Glucagon-Like Peptide 1--adverse effects<br/>Glycated Hemoglobin--metabolism<br/>Humans<br/>Hypoglycemic Agents--adverse effects<br/>Insulin--adverse effects<br/>Kaplan-Meier Estimate<br/>Male<br/>Metformin--therapeutic use<br/>Middle Aged<br/>Obesity--complications<br/>Propensity Score<br/>Proportional Hazards Models<br/>Retrospective Studies<br/>Risk Assessment<br/>Risk Factors<br/>Sulfonylurea Compounds--therapeutic use<br/>Time Factors<br/>Treatment Outcome<br/>United Kingdom